Here are three things to know:
1. Ortho RTi’s proprietary platform consists of the biopolymer chitosan, which is intended to be directly placed into the injury site during routine operative procedures.
2. The company develops treatments for rotator cuff and meniscus injuries.
3. The company issued a total of 450,000 Class “A” shares pursuant to the second tranche of its previously announced non-brokered private placement.
More articles on biologics:
23 developments in spine & orthopedic biologics research in 2018
